Genetic Correlations of Brain Lesion Distribution in Multiple Sclerosis: An Exploratory Study

References

1. 1.↵
   1. Lucchinetti C,
   2. Bruck W,
   3. Parisi J,
   4. et al

   . Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47:707–17

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Hooper-van Veen T,
   2. Berkhof J,
   3. Polman CH,
   4. et al

   . Analysing the effect of candidate genes on complex traits: an application in multiple sclerosis. Immunogenetics 2006;58:347–54.Epub 2006 Apr 13

   CrossRefPubMed
3. 3.↵
   1. Narayanan S,
   2. Fu L,
   3. Pioro E,
   4. et al

   . Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol 1997;41:385–91

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Barkhof F,
   2. Filippi M,
   3. Miller DH,
   4. et al

   . Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120 (pt 11):2059–69

   Abstract/FREE Full Text
5. 5.↵
   1. van Walderveen MA,
   2. Barkhof F,
   3. Tas MW,
   4. et al

   . Patterns of brain magnetic resonance abnormalities on T2-weighted spin echo images in clinical subgroups of multiple sclerosis: a large cross-sectional study. Eur Neurol 1998;40:91–98

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Di Perri C,
   2. Battaglini M,
   3. Stromillo ML,
   4. et al

   . Voxel-based assessment of differences in damage and distribution of white matter lesions between patients with primary progressive and relapsing-remitting multiple sclerosis. Arch Neurol 2008;65:236–43

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Vellinga MM,
   2. Geurts JJ,
   3. Rostrup E,
   4. et al

   . Clinical correlations of brain lesion distribution in multiple sclerosis. J Magn Reson Imaging 2009;29:768–73

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Lee MA,
   2. Smith S,
   3. Palace J,
   4. et al

   . Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis? Brain 1999;122 (pt 7):1261–70

   Abstract/FREE Full Text
9. 9.↵
   1. Koziol JA,
   2. Wagner S,
   3. Sobel DF,
   4. et al

   . Asymmetries in the spatial distributions of enhancing lesions and black holes in relapsing-remitting MS. J Clin Neurosci 2005;12:895–901

   CrossRefPubMed
10. 10.↵
    1. Dyment DA,
    2. Ebers GC,
    3. Sadovnick AD

    . Genetics of multiple sclerosis. Lancet Neurol 2004;3:104–10

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Hafler DA,
    2. Compston A,
    3. Sawcer S,
    4. et al

    . Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007;357:851–62

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Sawcer S,
    2. Ban M,
    3. Maranian M,
    4. et al

    . A high-density screen for linkage in multiple sclerosis. Am J Hum Genet 2005;77:454–67

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Baranzini SE,
    2. Wang J,
    3. Gibson RA,
    4. et al

    . Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet 2009;15;18:767–78.Epub 2008 Nov 14
14. 14.↵
    1. Barcellos LF,
    2. Oksenberg JR,
    3. Green AJ,
    4. et al

    . Genetic basis for clinical expression in multiple sclerosis. Brain 2002;125:150–58

    Abstract/FREE Full Text
15. 15.↵
    1. DeLuca GC,
    2. Ramagopalan SV,
    3. Herrera BM,
    4. et al

    . An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. Proc Natl Acad Sci U S A 2007;104:20896–901.Epub 2007 Dec 17.

    Abstract/FREE Full Text
16. 16.↵
    1. Hoffmann S,
    2. Cepok S,
    3. Grummel V,
    4. et al

    . HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am J Hum Genet 2008;83:219–27

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Kantarci OH,
    2. de Andrade M,
    3. Weinshenker BG

    . Identifying disease modifying genes in multiple sclerosis. J Neuroimmunol 2002;123:144–59

    CrossRefPubMedWeb of Science
18. 18.↵
    1. van Veen T,
    2. van Winsen L,
    3. Crusius JB,
    4. et al

    . [Alpha]B-crystallin genotype has impact on the multiple sclerosis phenotype. Neurology 2003;61:1245–49

    Abstract/FREE Full Text
19. 19.↵
    1. Deen S,
    2. Bacchetti P,
    3. High A,
    4. et al

    . Predictors of the location of multiple sclerosis relapse. J Neurol Neurosurg Psychiatry 2008;79:1190–93

    Abstract/FREE Full Text
20. 20.↵
    1. Mowry EM,
    2. Deen S,
    3. Malikova I,
    4. et al

    . The onset location of multiple sclerosis predicts the location of subsequent relapses. J Neurol Neurosurg Psychiatry 2009;80:400–03

    Abstract/FREE Full Text
21. 21.↵
    1. Butterfield RJ,
    2. Blankenhorn EP,
    3. Roper RJ,
    4. et al

    . Identification of genetic loci controlling the characteristics and severity of brain and spinal cord lesions in experimental allergic encephalomyelitis. Am J Pathol 2000;157:637–45

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Sombekke MH,
    2. Lukas C,
    3. Crusius JB,
    4. et al

    . HLA-DRB1*1501 and spinal cord magnetic resonance imaging lesions in multiple sclerosis. Arch Neurol 2009;66:1531–36

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Sepulcre J,
    2. Masdeu JC,
    3. Palacios R,
    4. et al

    . HLA-DR2 and white matter lesion distribution in MS. J Neuroimaging 2008;18:328–31

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Poser CM,
    2. Paty DW,
    3. Scheinberg L,
    4. et al

    . New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227–31

    CrossRefPubMedWeb of Science
25. 25.↵
    1. McDonald WI,
    2. Compston A,
    3. Edan G,
    4. et al

    . Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121–27

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Polman CH,
    2. Reingold SC,
    3. Edan G,
    4. et al

    . Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria.”Ann Neurol 2005;58:840–46

    CrossRefPubMedWeb of Science
27. 27.↵
    1. Kurtzke JF

    . Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444–52

    Abstract/FREE Full Text
28. 28.↵
    1. de Bakker PI,
    2. McVean G,
    3. Sabeti PC,
    4. et al

    . A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. Nat Genet 2006;38:1166–72

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Godde R,
    2. Rohde K,
    3. Becker C,
    4. et al

    . Association of the HLA region with multiple sclerosis as confirmed by a genome screen using >10,000 SNPs on DNA chips. J Mol Med 2005;83:486–94

    CrossRefPubMedWeb of Science
30. 30.↵
    1. Tejedor D,
    2. Castillo S,
    3. Mozas P,
    4. et al

    . Reliable low-density DNA array based on allele-specific probes for detection of 118 mutations causing familial hypercholesterolemia. Clin Chem 2005;51:1137–44

    Abstract/FREE Full Text
31. 31.↵
    1. van Walderveen MA,
    2. Barkhof F,
    3. Hommes OR,
    4. et al

    . Correlating MRI and clinical disease activity in Multiple Sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin echo images. Neurology 1995;45:1684–90

    Abstract/FREE Full Text
32. 32.↵
    1. Smith SM

    . Fast robust automated brain extraction. Hum Brain Mapp 2002;17:143–55

    CrossRefPubMedWeb of Science
33. 33.↵
    1. Mazziotta JC,
    2. Toga AW,
    3. Evans A,
    4. et al

    . A probabilistic atlas of the human brain: theory and rationale for its development—The International Consortium for Brain Mapping (ICBM).Neuroimage 1995;2:89–101

    CrossRefPubMedWeb of Science
34. 34.↵
    1. Smith SM,
    2. Jenkinson M,
    3. Woolrich MW,
    4. et al

    . Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004;2 (suppl 1):S208–19
35. 35.↵
    1. Nichols TE,
    2. Holmes AP

    . Nonparametric permutation tests for functional neuroimaging: a primer with examples. Hum Brain Mapp 2002;15:1–25

    CrossRefPubMedWeb of Science
36. 36.↵
    1. Fernando MM,
    2. Stevens CR,
    3. Walsh EC,
    4. et al

    . Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet 2008;4:e1000024

    CrossRefPubMed
37. 37.↵
    1. Zivadinov R,
    2. Uxa L,
    3. Zacchi T,
    4. et al

    . HLA genotypes and disease severity assessed by magnetic resonance imaging findings in patients with multiple sclerosis. J Neurol 2003;250:1099–106

    CrossRefPubMedWeb of Science
38. 38.↵
    1. Zivadinov R,
    2. Uxa L,
    3. Bratina A,
    4. et al

    . HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis. Int Rev Neurobiol 2007;79:521–35

    CrossRefPubMedWeb of Science
39. 39.↵
    1. Healy BC,
    2. Liguori M,
    3. Tran D,
    4. et al

    . HLA B*44: protective effects in MS susceptibility and MRI outcome measures. Neurology 2010;75:634–40

    Abstract/FREE Full Text
40. 40.↵
    1. Barcellos LF,
    2. Oksenberg JR,
    3. Begovich AB,
    4. et al

    . HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet 2003;72:710–16

    CrossRefPubMedWeb of Science
41. 41.↵
    1. Lincoln MR,
    2. Montpetit A,
    3. Cader MZ,
    4. et al

    . A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat Genet 2005;37:1108–12

    CrossRefPubMedWeb of Science
42. 42.↵
    1. Wattjes MP,
    2. Lutterbey GG,
    3. Harzheim M,
    4. et al

    . Higher sensitivity in the detection of inflammatory brain lesions in patients with clinically isolated syndromes suggestive of multiple sclerosis using high field MRI: an intraindividual comparison of 1.5 T with 3.0 T. Eur Radiol 2006;16:2067–73

    CrossRefPubMedWeb of Science
43. 43.↵
    1. Geurts JJ,
    2. Barkhof F

    . Grey matter pathology in multiple sclerosis. Lancet Neurol 2008;7:841–51

    CrossRefPubMedWeb of Science
44. 44.↵
    1. Witte ME,
    2. Bo L,
    3. Rodenburg RJ,
    4. et al

    . Enhanced number and activity of mitochondria in multiple sclerosis lesions. J Pathol. 2009;219:193–204

    CrossRefPubMedWeb of Science
45. 45.↵
    1. van Veen T,
    2. Nielsen J,
    3. Berkhof J,
    4. et al

    . CCL5 and CCR5 genotypes modify clinical, radiological and pathological features of multiple sclerosis. J Neuroimmunol 2007;190:157–64

    CrossRefPubMedWeb of Science
46. 46.↵
    1. Baranzini SE,
    2. Galwey NW,
    3. Wang J,
    4. et al

    . Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Hum Mol Genet 2009;18:2078–90

    Abstract/FREE Full Text